Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos, sex toys and adult toys.
Popular Articles

Dental Health Advocates Want To Sink Teeth Into Health Care Reform
The Washington Post reports many oral health professionals worry that dental issues have "a tenuous place at best in the national debate" regarding an overhaul of the health care system. Still, they emphasize that dental health is an integral part of health care and note the special burden untreated dental issues have on poor children. The paper also notes that "closing the gap between the worlds of dental care and medical care, with their separate histories and cultures, and their separate finance and delivery systems would be a formidable task."
buy viagra
Childbirth-Related Injuries Decline, Linked With Use Of Instruments, AHRQ Report Finds
There were nearly 158,000 potentially avoidable childbirth-related injuries to women and their infants in 2006, a significant decline from 2000, according to a report by the Agency for Healthcare Research and Quality, HealthLeaders Media reports. The report used data submitted for 15 million discharges by 1,900 hospitals in 25 states, including the largest states -- California, New York, Florida and Texas. Between 2000 and 2006, the rate of potentially avoidable injuries during vaginal childbirth without the use of instruments, such as forceps, declined by 30%, according to the report. The injury rate declined by 21.3% for vaginal childbirth using instruments and by 16.7% for women undergoing caesarean sections. Report author Roxanne Andrews of AHRQ said that the report did not examine factors that might have contributed to the declining injury rates but added that it is an area for further study.The report found that rates of injury were higher when instruments were used during childbirth. For instance, trauma to the woman during vaginal delivery with the use of instruments occurred 160.5 times per 1,000 discharges, compared with 36.2 times when instruments were not used. The report said that the most common injuries to women were perineum tears, which are avoidable in many cases. Traumatic injury to infants during childbirth -- such as broken collarbones, head injuries and infections -- occurred 1.6 times per 1,000 discharges.The report also highlighted care disparities between women in low-income areas and those in high-income areas. Women giving birth in high-income areas had 44% more injuries during vaginal delivery than their counterparts in low-income areas. Black and Hispanic women experienced fewer injuries than white women, while Asian American and Pacific Islander women experienced the highest rate of injuries. The report found that women covered by Medicaid were less likely to be injured during childbirth -- 127 injuries per 1,000 deliveries -- compared with women with private insurance plans -- 185 injuries per 1,000 deliveries. However, the rate of injury for infants covered under Medicaid was higher -- 1.7 per 1,000 deliveries -- than those under private plans -- 1.5 per 1,000 deliveries.The report encouraged providers to evaluate their practices to better understand why such complications occur. According to the report, "Identifying which types of patient safety problems exist for different sub-groups of patients is an important first step in developing interventions to reduce disparities and achieve high quality of care for all patients" (Clark, HealthLeaders Media, 6/18).
plan for health
News of the day
BMA Scotland Chairman Urges MSPs Not To Play Politics With Public Health
Speaking at the Annual Conference of the British Medical Association (BMA), Dr Peter Terry, chairman of the BMA Scotland urged MSPs to put party politics aside and stand together to improve health. He also underlined the need for legislation on the price of alcohol as an effective measure to tackle Scotland"s drink problem.
Mental Health

Provectus Completes Patient Accrual In Phase 2 Trial Of PV-10 For Metastatic Melanoma

Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company has completed patient accrual and initial PV-10 treatment in its Phase 2 trial of PV-10 for metastatic melanoma. The study involved treatment of 80 subjects with Stage III or Stage IV metastatic melanoma. Dr. Craig Dees, PhD, CEO of Provectus said, "It is gratifying to have reached our patient enrollment objective in the Phase 2 trial of PV-10 for metastatic melanoma and we are pleased with the interim efficacy and safety results that have been achieved and reported on the first 20 patients enrolled in the trial. Completion of the enrollment phase of the trial brings us another step closer in our efforts to find a treatment that may help the estimated 120,000 patients in the U.S. alone who are afflicted with this devastating disease. With an estimated 48,000 global deaths having occurred last year from Stage III or Stage IV melanoma, we remain focused on furthering our work aimed at developing a safe and effective treatment. We look forward to communicating detailed Phase 2 interim results at the American Society of Clinical Oncology (ASCO) Scientific Program on June 1, 2009 in Orlando, Florida." He continued, "Also noteworthy is that even though this phase of the trials has concluded, our investigators have requested that they be allowed to treat more patients. Therefore, we are implementing a compassionate use program for melanoma so patients in need can continue to obtain access to PV-10 while we pursue regulatory approval in the U.S. and abroad." The primary objective of the Phase 2 study is to investigate the effectiveness of intralesional (IL) PV-10 for locoregional treatment of metastatic melanoma. The study also includes assessment of response in untreated bystander lesions following intralesional injection of PV-10 into treated lesions. Additional objectives of the trial are to determine the safety profile of PV-10 following intralesional injection, and assess the pharmacokinetic profile of PV-10 in the bloodstream following intralesional injection. The Phase 2 study is an interventional, open-label, multicenter, single group assignment safety/efficacy study. To accurately reflect anticipated clinical use, repeat dosing of lesions not exhibiting complete response is allowed at the investigator"s discretion several times following initial treatment. Subjects are followed for 52 weeks following initial treatment with PV-10. About PV-10 PV-10 is a proprietary, injectable formulation of Rose Bengal, a compound that has been in use for nearly thirty years by ophthalmologists and optometrists to assess damage to the eye. It has also been used to detect ailments of the liver. Rose Bengal has an established safety history, a short half-life in the bloodstream, and is excreted via the liver and kidneys. Provectus has discovered a novel use for Rose Bengal based on the observation that it is selectively toxic to cancer calls via a process called chemoablation whereby cells undergo a form of cell death that mimics both features of necrosis and apoptosis. Provectus Pharmaceuticals, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009